Latest news with #T2D
Medscape
3 days ago
- Health
- Medscape
Diabetes Drug Tied to Decreased Dementia Risk in T2D
TOPLINE: Semaglutide was associated with a 20%-46% reduced risk for Alzheimer's disease (AD)-related dementia in patients with type 2 diabetes (T2D) compared with other antidiabetic medications, with a particularly strong protective effect against vascular dementia, new research showed. METHODOLOGY: Researchers examined electronic health records (EHRs) of more than 1.7 million US adults with T2D with or without obesity and with no prior diagnosis of AD or AD-related dementia. They compared semaglutide (n = 64,267 users) to seven other antidiabetic medications (n = 1,646,728 users) on the first-time diagnosis of AD-related dementia, as well as the subtypes of vascular dementia, frontotemporal dementia (FTD), and Lewy body dementia, during a 3-year follow-up. The other antidiabetic medications included insulin, metformin, DPP-4 inhibitors, SGLT2 inhibitors, sulfonylurea, thiazolidinedione, and first-generation GLP-1 receptor agonists (albiglutide, dulaglutide, exenatide, liraglutide, and lixisenatide). Secondary outcomes included prescriptions of dementia-related medications. TAKEAWAY: Semaglutide was associated with a significantly reduced risk for AD-related dementia compared to insulin (hazard ratio [HR], 0.54), metformin (HR, 0.67), and older GLP-1 receptor agonists (HR, 0.80). Protection against vascular dementia was also greater for semaglutide compared to insulin (HR, 0.48), metformin (HR, 0.55), and GLP-1 receptor agonists (HR, 0.67). No significant associations were found between the use of semaglutide and the risk for FTD or Lewy body dementia. The link between semaglutide and reduced AD-related dementia risk vs insulin, metformin, and GLP-1 receptor agonists was stronger in younger adults (mean age, 51.7 years) compared to older adults (mean age, 70.9 years), with risk reductions ranging from 32% to 56% vs 20% to 39%. The use of semaglutide vs other antidiabetic medications was associated with significantly fewer prescriptions of dementia-related medications. IN PRACTICE: 'There is no cure or effective treatment for dementia, so this new study provides real-world evidence for its potential impact on preventing or slowing dementia development among at high-risk population,' Rong Xu, Case Western Reserve University School of Medicine, Cleveland, said in a press release. 'Future works are needed to establish causal relationships through randomized clinical trials and to characterize the underlying mechanisms,' the investigators wrote. SOURCE: This study was led by William Wang, Case Western Reserve University School of Medicine, Cleveland. It was published online on June 24 in the Journal of Alzheimer's Disease. LIMITATIONS: This retrospective, observational, EHR-based study was limited by potential over-, under-, or misdiagnosis; unmeasured confounders; and a short 3-year follow-up period. Diagnosis of AD-related dementia relied on International Classification of Diseases, 10th Revision codes and prescription data, which may have lacked precision. This study also lacked data on medication adherence, cognitive function tracking, and genetic profiles, and could not fully adjust for variation of healthcare use. DISCLOSURES: This study was funded by grants from the National Institute on Aging and the National Center for Advancing Translational Sciences. One investigator reported being the editor in chief of the publishing journal but was not involved in the peer-review process. The other investigators reported having no relevant financial conflicts. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
3 days ago
- Business
- Yahoo
Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth?
Eli Lilly LLY has experienced significant growth in the past few years, particularly driven by the success of its popular tirzepatide injections, Mounjaro for type II diabetes (T2D) and Zepbound for obesity. Despite being on the market for less than three years, GLP-1 medicines, Mounjaro and Zepbound, became key top-line drivers for Lilly, with demand rising rapidly. However, to maintain its prowess in the lucrative obesity market, especially in the United States, Lilly is investing heavily in obesity and has several new molecules currently in clinical development. This includes two late-stage candidates, orforglipron, an oral GLP-1 small molecule, and retatrutide, a triple-acting incretin and some mid-stage candidates, bimagrumab, eloralintide and mazdutide. Earlier this year, Lilly announced data from the first of the seven phase III studies on orforglipron in T2D and obesity. In the study, orforglipron lowered A1C by an average of 1.3-1.6% across doses and also reduced weight by an average of 16lb (7.9%) at the highest dose. Lilly expects to report additional results from the phase III ACHIEVE clinical program, as well as data from the phase III ATTAIN clinical program evaluating orforglipron for obesity, later this year. It plans to file regulatory applications for obesity by the end of this year and for T2D in the first half of 2026. Eli Lilly's GLP-1 drugs face strong competition from Novo Nordisk's NVO semaglutide products, Wegovy (obesity) and Ozempic (T2D). Like LLY, NVO is also evaluating several next-generation weight loss candidates. The notable ones include CagriSema, a fixed-dose combination of a long-acting amylin analogue and Wegovy, for which regulatory submission for the weight loss indication is planned in 2026. Novo Nordisk is also developing an early-stage candidate, amycretin, a unimolecular GLP-1 and amylin receptor agonist, which had outperformed Wegovy in a phase I study. NVO has also filed a regulatory application for an oral version of Wegovy. Several other companies, like Viking Therapeutics VKTX, are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline. Viking Therapeutics' dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity. Recently, Viking Therapeutics initiated a late-stage program (VANQUISH), comprising two phase III studies evaluating the subcutaneous version of VK2735 in obesity and T2D patients. VKTX had also initiated a mid-stage study (VENTURE) on the oral formulation of the candidate earlier this year. Shares of Eli Lilly have risen 2.6% so far this year against the industry's decline of 1.9%. The stock has outperformed the sector but underperformed the S&P 500 index during the same time frame, as seen in the chart below. Image Source: Zacks Investment Research From a valuation standpoint, Lilly's stock is expensive. Going by the price/earnings ratio, the company's shares currently trade at 30.14 forward earnings, higher than 14.92 for the industry. However, the stock is trading below its five-year mean of 34.54. Image Source: Zacks Investment Research Estimates for Eli Lilly's 2025 earnings have declined from $22.43 to $21.95 per share in the past 60 days, and estimates for 2026 earnings have declined from $31.15 to $30.91 over the same timeframe. Image Source: Zacks Investment Research Eli Lilly currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
5 days ago
- Business
- Yahoo
Amgen (AMGN) Falls 5.8% as Novo Nordisk Hammers Its Weight Loss Drug Trial
Amgen Inc. (NASDAQ:AMGN) is one of the . Amgen Inc. extended its losing streak to a fourth straight day on Monday, dropping 5.84 percent to close at $272.44 apiece as investors sold off positions despite positive results from its weight loss drug trial, after Novo Nordisk—maker of the blockbuster Wegovy and Ozempic—progressed in its second obesity drug trial. In a statement on Monday, Amgen Inc. (NASDAQ:AMGN) announced that its phase 2 study of its weight loss drug candidate, MariTide, demonstrated up to 20 percent average weight loss in people living with obesity without Type 2 Diabetes (T2D), and up to 17 percent for people living with obesity with T2D. However, investors seemed unimpressed, following Novo Nordisk's announcement over the weekend that its new obesity drug candidate, Amycretin, has progressed to a phase 3 trial after demonstrating 24.3 percent weight loss, higher than Amgen Inc.'s (NASDAQ:AMGN). A pharmacist filling a prescription for a complex drug developed by the company. Additionally, investor sentiment was dampened by an announcement that Amgen Inc.'s (NASDAQ:AMGN) MariTide dosing should be less frequent to improve adherence and long-term weight control. While we acknowledge the potential of AMGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Health
- Yahoo
Biomea Fusion announces presentation of icovamenib preclinical, clinical data
Biomea Fusion (BMEA) announced the presentation of new preclinical and clinical data for icovamenib, the company's investigational oral menin inhibitor, at the 85th Scientific Sessions of the American Diabetes Association June 20-23, 2025 in Chicago. Biomea presented three abstracts: one oral presentation and two posters, all highlighting icovamenib's therapeutic potential across key dimensions of T2D pathophysiology, including its impact on beta cell restoration, and synergy with glucagon-like peptide-1 receptor agonists to promote metabolic health and selective fat loss with complete lean mass preservation. Presentation Summaries: Title: Combination Therapy of Icovamenib and Semaglutide Enhances Body Weight Loss and Glycemic Control While Preserving Lean Mass in a Type 2 Diabetes Animal Model: Summary: In a Zucker Diabetic Fatty rat model of T2D, treatment of icovamenib in combination with low-dose semaglutide delivered superior metabolic benefits compared to low-dose semaglutide alone: 60% lower fasting blood glucose and 50% lower glucose OGTT AUC; Greater HbA1c decline; greater than1% by Day 28 and greater than2% by Day 39; Greater improvement in insulin sensitivity with a 75% lower HOMA-IR; 2-fold increase in C-peptide to glucose ratio indicating enhanced beta cell function; Superior appetite suppression with a 10% greater body weight reduction than low-dose semaglutide alone; The observed body weight loss was primarily due to fat mass reduction with complete preservation of lean mass; These findings support the potential of icovamenib to enhance the therapeutic effects of GLP-1-based therapies. The combination may allow lower doses of GLP-1-based therapies to achieve glycemic and weight loss targets and improve tolerability of these agents, offering a compelling rationale for clinical evaluation of icovamenib-based combination regimens. Title: Icovamenib Rescues Human Myotube Atrophy Ex Vivo and Displays Complete Lean Mass Preservation in a Type 2 Diabetes Rat Model: Summary: This preclinical study evaluated icovamenib's direct effects on ex vivo human myotube cultures and the effects of icovamenib in combination with low-dose semaglutide in an in vivo rodent model of diabetes: In ex vivo cultures of iPSC-derived 3D-engineered human myotubes, icovamenib treatment promoted healthy myotube morphology; Separately, icovamenib diminished drug-induced atrophy by activin A or dexamethasone, suggesting muscle health supporting effects of icovamenib; In a ZDF rat study, combination treatment with icovamenib and low-dose semaglutide induced greater body weight reduction with complete preservation of lean mass, outperforming low-dose semaglutide; These early findings support icovamenib's unique potential when combined with GLP-1-based therapies to enhance body weight reduction and protect lean mass, a highly desirable feature for any long-term diabetes or obesity therapy. Title: COVALENT-111: 26-Week Efficacy and Safety after 8 and 12 Weeks of Daily Oral Icovamenib in Patients with Poorly Controlled Type 2 Diabetes: Summary: 26-week follow-up results from the ongoing Phase II COVALENT-111 trial highlight the potential of short-course oral icovamenib treatment to deliver durable glycemic control and improved beta cell function, in patients with poorly controlled T2D, particularly in the insulin-deficient subgroup. Key findings include: Icovamenib achieved a 1.0% placebo-adjusted mean HbA1c reduction and a 55% increase in C-peptide in severe insulin-deficient participants at Week 26, three months after the last dose; Over half of the C-peptide improvement occurred during the off-treatment period, indicating a durable effect on endogenous insulin production; Short-course dosing led to sustained HbA1c reductions through Week 26 across the broader study population; Changes in HbA1c correlated significantly with changes in C-peptide, supporting the proposed mechanism of action to restore beta-cell function; In patients inadequately controlled on baseline GLP-1 RA therapy, icovamenib added to the GLP-1 RA led up to an additional 1.0% mean HbA1c reduction. Icovamenib was well tolerated across all dosing arms, with a low incidence of treatment-emergent adverse events, no clinically significant elevations in ALT or AST, and no study drug discontinuations or discontinuations from the trial due to adverse events Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
20-06-2025
- Health
- Medscape
Switch to Water From Diet Sodas May Boost Diabetes Remission
TOPLINE: Regularly substituting water for diet beverages contributed to greater weight loss and was associated with a twofold increase in the diabetes remission rate among women with type 2 diabetes (T2D) and obesity or overweight. METHODOLOGY: Diet sodas, despite being calorie-free, may affect the body differently from water, and their regular consumption is linked to potential health risks, including cardiovascular disease, T2D, and obesity. Researchers conducted an 18-month study to evaluate the effects of replacing diet beverages with water. The study included 81 adult women with T2D and obesity or overweight who participated in a weight-management program and regularly consumed diet beverages. Participants were randomly assigned to replace diet beverages with water or to maintain their usual intake of five diet drinks per week, consumed after lunch. All participants underwent a 6-month weight-loss program, followed by a 12-month maintenance program. TAKEAWAY: Women in the water group experienced a greater average weight loss (-6.82 ± 2.73 kg) than the diet beverage group (-4.85 ± 2.07 kg; P < .001). Diabetes remission was achieved by 90% of participants in the water group compared with 45% of those in the diet beverage group (P < .0001). Significant improvements were noted in BMI, fasting glucose, postprandial glucose, insulin, triglyceride levels, and insulin resistance in the water group. IN PRACTICE: "These findings challenge a common belief in the US that diet drinks have no potential negative effects for managing weight and blood sugar," Hamid R. Farshchi, MD, PhD, CEO of the digital platform D2Type, said in a press release. "However, with most of the women in the water group achieving diabetes remission, our study highlights the importance of promoting water, not just low-calorie alternatives, as part of effective diabetes and weight management. It's a small change with the potential for a big impact on long-term health outcomes." SOURCE: The study was led by Hamid R. Farshchi, MD, PhD, of D2Type, and former associate professor at the University of Nottingham, School of Life Sciences. It was presented as a poster on June 22, 2025, at the 85th Scientific Sessions - American Diabetes Association held at the McCormick Place Convention Center, Chicago (June 20-23, 2025). LIMITATIONS: No limitations were discussed in the press release. DISCLOSURES: No disclosures or conflict-of-interest statements were provided. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
